Posted by Michael Wonder on 03 Aug 2026
New chemotherapy-free immunotherapy combination for follicular lymphoma listed on the PBS
2 August 2026 - Independent biopharmaceutical company Specialised Therapeutics is pleased to announce the listing of Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, on the PBS for the treatment of Australian adults with relapsed or refractory follicular lymphoma (Grade 1-3a).
This milestone follows the Australian registration of Minjuvi for relapsed or refractory follicular lymphoma by the TGA in April 2026, via the Project Orbis process.
